Yingtai Medical (01501) plans to spend about 55.1202 million US dollars to further acquire shares in Dejin Medical

According to Zhitong Finance App News, Yingtai Medical (01501) announced that in connection with the separate acquisition of the target company's total issued share capital of about 23.18% and 0.79%, the company and its designated wholly-owned subsidiary (that is, the transferee) entered into a partnership rights transfer agreement with several existing partners (i.e. transferors) of Shanghai Yuyi on July 23, 2026. Based on this, the transferee has agreed to receive 100% of Shanghai Kuanyi's partnership interests domestically, with a total consideration of about US$55.1202 million. Shanghai Yuanyi indirectly holds 579,866 Series B preferred shares of the target company, accounting for about 3.85% of the total issued share capital of the target company.

The target company is Valgen Holding Corporation, which holds 100% of Dejin Healthcare's shares. The target company is a holding company with no substantial business activity. Dejin Medical is mainly engaged in R&D, production and sales of interventional treatment techniques and products for atrioventricular valve diseases (especially mitral and tricuspid valve interventional treatment). Dejin Medical is the target group's main operating entity in China.

^{The four products independently developed by the Target Group have been included in the special review process for innovative medical devices by the State Drug Administration, namely Mitral Stitch® transcatheter mitral valve repair system, Dragon Fly™ transcatheter mitral valve clamp system, Dragon Fly-T® transcatheter tricuspid valve clip system, and Dragon Fire® transcatheter myocardial radiofrequency ablation system.} Among them, the Dragon Fly™ transcatheter mitral valve clip system is the first domestically produced transcatheter mitral valve product approved by the State Drug Administration.

After the completion of the initial acquisition, the second acquisition and the third acquisition, the company will hold (directly and indirectly through Shanghai Yuanyi and Max) a total of 4,193,775 shares of the target company, accounting for about 27.82% of the total issued share capital of the target company.

The board of directors believes that the acquisition of shares in the target company provides the company with an opportunity to supplement its structural heart disease product pipeline to achieve more comprehensive product coverage in this field and enhance the Group's overall competitiveness and long-term development potential in the field of cardiovascular intervention. The purpose of the third acquisition is to implement the company's strategy to gradually increase its shareholding in the target company. The transaction structure under the partnership rights transfer agreement is generally in line with the company's policy of acquiring shares in the target company from existing investors, and is also consistent with the acquisition plan previously disclosed by the target company's shareholders.